A LinkedIn post from ThinkCyte highlights the company’s presence at the SLAS 2026 conference in Boston, where it is showcasing its Ghost Cytometry technology at Booth 1827. The post suggests the platform integrates high-speed, label-free cell sorting with real-time AI analysis aimed at streamlining drug discovery and phenotypic screening workflows.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The company’s LinkedIn content also points to two scientific posters focused on immune cell phenotyping and senescence biomarker profiling using its VisionSort Morphometry approach. For investors, this visibility at a specialized industry conference may support ThinkCyte’s positioning in advanced flow cytometry and AI-enabled cell analysis, potentially aiding future commercial traction in drug discovery, CRISPR screening, and regenerative medicine markets.